Literature DB >> 1353190

Abnormal expression of wild type p53 protein in normal cells of a cancer family patient.

D M Barnes1, A M Hanby, C E Gillett, S Mohammed, S Hodgson, L G Bobrow, I M Leigh, T Purkis, C MacGeoch, N K Spurr.   

Abstract

Mutations in the p53 gene are the commonest specific genetic change in human cancer. In normal tissues, p53 protein is present in such low quantities that it is not readily detectable by immunochemical techniques. However, in many tumour cells large amounts of p53 protein accumulate and can be seen by simple immunohistochemical staining; this is generally attributed to the accumulation of stabilised, mutant protein. We have found a mother and daughter, who both have a history of breast cancer, who show strong immunohistochemical staining of p53 in most of their normal epithelial and mesenchymal cells. Their family has a history of multiple cancers developing at an early age. Detailed protein analysis and gene sequencing of material obtained from cultured cells, grown from a skin biopsy taken from the daughter, suggest that her cells contained large quantities of normal (unmutated) p53. We suggest that this phenotype defines a new inherited cancer susceptibility syndrome that is distinct from the germ-line mutations in p53 found in some Li-Fraumeni families. This new syndrome affects p53 tumour suppressor function through an indirect mechanism that stabilises normal p53. It remains to be established whether this mechanism also contributes to the accumulation of p53 in sporadic cancers.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1353190     DOI: 10.1016/0140-6736(92)92354-i

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  42 in total

Review 1.  Cancer risks from germline p53 mutations.

Authors:  T Frebourg; S H Friend
Journal:  J Clin Invest       Date:  1992-11       Impact factor: 14.808

2.  MDM2/p53 protein expression in the development of colorectal adenocarcinoma.

Authors:  G Abdel-Fattah; B Yoffe; B Krishnan; V Khaoustov; K Itani
Journal:  J Gastrointest Surg       Date:  2000 Jan-Feb       Impact factor: 3.452

3.  An extended Li-Fraumeni kindred with gastric carcinoma and a codon 175 mutation in TP53.

Authors:  J M Varley; G McGown; M Thorncroft; K J Tricker; M D Teare; M F Santibanez-Koref; J Martin; J M Birch; D G Evans
Journal:  J Med Genet       Date:  1995-12       Impact factor: 6.318

4.  Apoptosis in rheumatoid arthritis: p53 overexpression in rheumatoid arthritis synovium.

Authors:  G S Firestein; K Nguyen; K R Aupperle; M Yeo; D L Boyle; N J Zvaifler
Journal:  Am J Pathol       Date:  1996-12       Impact factor: 4.307

5.  Detection of p53 in inflammatory tissue and lymphocytes using immunohistology and flow cytometry: a critical comment.

Authors:  A Nickels; H Selter; M Pfreundschuh; M Montenarh; B Koch
Journal:  J Clin Pathol       Date:  1997-08       Impact factor: 3.411

6.  Heterogeneity in Li-Fraumeni families: p53 mutation analysis and immunohistochemical staining.

Authors:  C MacGeoch; G Turner; L G Bobrow; D M Barnes; D T Bishop; N K Spurr
Journal:  J Med Genet       Date:  1995-03       Impact factor: 6.318

7.  Germline p53 mutations are frequently detected in young children with rhabdomyosarcoma.

Authors:  L Diller; E Sexsmith; A Gottlieb; F P Li; D Malkin
Journal:  J Clin Invest       Date:  1995-04       Impact factor: 14.808

Review 8.  Biological features of premalignant disease in the human breast.

Authors:  D C Allred; S K Mohsin
Journal:  J Mammary Gland Biol Neoplasia       Date:  2000-10       Impact factor: 2.673

9.  Mutation of p53 in primary biopsy material and cell lines from Hodgkin disease.

Authors:  R K Gupta; K Patel; W F Bodmer; J G Bodmer
Journal:  Proc Natl Acad Sci U S A       Date:  1993-04-01       Impact factor: 11.205

10.  Effects of 2-amino-4,6-dinitrotoluene on p53 tumor suppressor gene expression.

Authors:  Hirendra Banerjee; Zack Hawkins; Sisir Dutta; Duane Smoot
Journal:  Mol Cell Biochem       Date:  2003-10       Impact factor: 3.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.